Y-Mabs Therapeutics Inc. has received FDA clearance of its IND application for CD38-SADA, the company’s second program within its SAYA Y-PRIT (Self-Assembly DisAssembly Pre-targeted Radioimmunotherapy) theranostic platform.

Cimeio Therapeutics Inc. has entered into a preclinical research collaboration with a researcher at the University of Pennsylvania (Penn) to research and evaluate a novel universal immunotherapy with potential to treat multiple blood and bone marrow cancers.

Transcode Therapeutics Inc. has reported successful treatment of preclinical melanoma...

In recent years, the introduction of immune checkpoint inhibitors to the oncolytic pipeline has been a significant breakthrough in cancer treatment, but unfortunately some tumors respond only minimally. Besides CTLA-4, and since the approval of PD-1/PD-L1 inhibitors, only the anti-LAG3 strategy (relatlimab, Bristol Myers Squibb Co.) has been good enough to reach the market. In a session dealing with emerging checkpoints beyond PD-1, CTLA-4 and LAG3, Drew Rasco from the START Center for Cancer Care depicted a new player on the ground of immunotherapeutic options.

Sotio Biotech AS, a company owned by PPF Group, has entered into a license and option agreement with Synaffix BV, a Lonza company, to develop next-generation antibody-drug conjugates (ADCs) for the treatment of solid tumors.

Medilink Therapeutics (Suzhou) Co. Ltd. has entered into a strategic research collaboration and worldwide license agreement with Biontech SE for the development of a next-generation antibody-drug conjugate candidate (ADC) against HER3.

Researchers from Panolos Bioscience Inc. and affiliated organizations have published preclinical data for PB-101, a novel glycosylated decoy protein targeting both vascular endothelial growth factor (VEGF) and placental growth factor (PlGF).

Sparx Group has formed a strategic alliance with Arovella Therapeutics Ltd. for the development of a CLDN18.2-chimeric antigen receptor (CAR)-invariant natural killer T (iNKT) cell therapy.